Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes.

Autor:	Leong DP; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.; Department of Medicine, McMaster University, Hamilton, Ontario, Canada., Fradet V; Centre de Recherche du CHU de Québec, Université Laval, Quebec City, Quebec, Canada., Niazi T; Jewish General Hospital, Montreal, Quebec, Canada., Selvanayagam JB; Southern Area Local Health Network and Flinders University of South Australia, Adelaide, Australia., Sabbagh R; Faculty of Medicine, University of Sherbrooke, Montreal, Quebec, Canada., Higano CS; University of British Columbia and Madrona Oncology, Seattle, Washington, USA., Agapay S; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada., Rangarajan S; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada., Mian R; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada., Nakashima CAK; Faculdades Pequeno Príncipe, Sociedade Hospitalar Angelina Caron, Araçatuba, Brazil., Mousavi N; McGill University Health Centre, Montreal, Quebec, Canada., Brown I; Division of Urology, Niagara Health System, St. Catharines, Ontario, Canada., Valle FH; Division of Cardiology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil., Lavallée LT; Division of Urology, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Shayegan B; Division of Urology, Department of Surgery, St. Joseph's Healthcare Hamilton and McMaster University, Hamilton, Ontario, Canada., Ng KKH; Department of Medicine, McMaster University, Hamilton, Ontario, Canada., Gopaul DD; Grand River Regional Cancer Centre, Kitchener, Ontario, Canada., Cavalli GD; Department of Medicine, McMaster University, Hamilton, Ontario, Canada., Saavedra S; Faculty of Medicine, University of La Frontera, Temuco, Chile., Lopez-Lopez JP; Masira Research Institute, Universidad de Santander, Bucaramanga, Colombia., Freitas de Souza C; Núcleo de Pesquisa Clínica - Rede São Camilo and Instituto Brasileiro de Controle do Cancer, São Paolo, Brazil., Duceppe E; Department of Medicine, Centre Hospitalier de l'Université de Montreal, Montreal, Quebec, Canada., Avezum Oliveira LF; Centro de Pesquisa Clínica do HC-UFTM, Uberaba, Brazil., Guha A; Augusta University, Augusta, Georgia, USA., Gomez-Mesa JE; Department of Health Sciences and Fundacíon Valle del Lili, Universidad Icesi, Cali, Colombia., Eduardo Silva Móz L; Clinical Oncology Department, Santa Casa de São Paolo Hospital, São Paolo, Brazil., Violette PD; Woodstock Hospital, McMaster University, Woodstock, Ontario, Canada., Avezum Á; International Research Center, Hospital Alemão Oswaldo Cruz, São Paolo, Brazil., Oliveira GBF; International Research Center, Hospital Alemão Oswaldo Cruz, São Paolo, Brazil., Kann AG; International Research Center, Hospital Alemão Oswaldo Cruz, São Paolo, Brazil., Walter E; Centro de Oncologia do Hospital de Clínicas Ijuí, Ijuí, Brazil., Dusilek COL; Hospital Rocio, Curitiba, Brazil., Villareal Trujillo N; FOSCAL Internacional Clinic, Floridablanca, Colombia., Beato P; Centro de Pesquisas Clínicas da Fundação Doutor Amaral Carvalho, São Paolo, Brazil., Hajjar LA; Faculdade de Medicina da Universidade de São Paolo, São Paolo, Brazil., Luke PPW; Department of Surgery, London Health Science Centre, London, Ontario, Canada., Schlabendorff E; Mãe de Deus Hospital, Porto Alegre, Brazil., Sarid D; Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel., Pinthus J; Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
Jazyk:	angličtina
Zdroj:	JACC. CardioOncology [JACC CardioOncol] 2024 Sep 03; Vol. 6 (5), pp. 761-771. Date of Electronic Publication: 2024 Sep 03 (Print Publication: 2024).
DOI:	10.1016/j.jaccao.2024.07.011
Abstrakt:	Background: There are limited data on the physical effects of androgen deprivation therapy (ADT) for prostate cancer (PC), and on the relationships of such measures of adiposity and strength to cardiovascular outcomes. Objectives: The primary objective of this study was to evaluate the relationships of measures of adiposity and strength to cardiovascular outcomes (cardiovascular death, myocardial infarction, stroke, heart failure, arterial revascularization, peripheral arterial disease, and venous thromboembolism) in patients with PC. A secondary objective was to characterize the relationships between ADT use and 12-month changes in these physical measures. Methods: This international, prospective cohort study included 3,967 patients with PC diagnosed in the prior 12 months or being treated with ADT for the first time. Median follow-up duration was 2.3 years. Results: Participants' mean age was 68.5 years, and 1,731 (43.6%) were exposed to ADT. ADT was associated with a 1.6% increase in weight, a 2.2% increase in waist circumference, a 1.6% increase in hip circumference, a 0.1% increase in waist-to-hip ratio, a 27.4% reduction in handgrip strength, and a 0.1% decrease in gait speed. High waist circumference and low handgrip strength were associated with adverse cardiovascular outcomes. Adjusting for age, education, race, tobacco and alcohol use, physical activity, cardiovascular disease, glomerular filtration rate, and ADT use, waist circumference above the highest quartile (110 cm) and handgrip strength below the lowest quartile (29.5 kg) were associated with higher likelihoods of a future cardiovascular event, with respective HRs of 1.40 (95% CI: 1.03-1.90; P  = 0.029) and 1.59 (95% CI: 1.14-2.22; P  = 0.006). Conclusions: ADT was associated with increased adiposity and reduced strength over 12-month follow-up. High waist circumference and low baseline strength were associated with future adverse cardiovascular outcomes. Competing Interests: Research support for this study was provided by the Movember Foundation, the Canadian Cancer Society, and Tolmar Pharmaceuticals. This study was presented in part at a Late-Breaking Science Session at the Scientific Sessions of the European Society of Cardiology, Amsterdam, the Netherlands, August 28, 2023. Dr Leong has received consultancy fees or honoraria from Abbvie, Ferring, Ipsen, Janssen, Jazz Pharmaceuticals, Myovant, Novartis, Pfizer, Sanofi, Antev, AstraZeneca, Bayer, Boston Scientific, and XFacto; and has received research support from Novartis and Tolmar. Dr Higano has received consultancy fees or honoraria from AstraZeneca, Astellas, Bayer, Genetech, Eli Lilly, Merck Sharp & Dohme, Myovant, Menarini, Tolmar, Vaccitech, and Verity; is a stockholder of CTI Biopharma; and is a data and safety monitoring board member or chair in trials sponsored by AstraZeneca, Advantagene, and Exelixis. Dr Lavallée is an advisory board member for Astellas, Knight, Bayer, and AAA; and has received a grant from Tolmar unrelated to the present work. Dr Gopaul is an advisory board member for and has received honoraria from TerSera, Bayer, Ferring, Abbvie, and Knight. Dr Duceppe has received grant funding from Roche Diagnostics and Abbott Laboratories. Dr Guha is an advisory board member for Pfizer, Myovant, and Novartis; and has received research grants from the American Heart Association (847740 and 863620) and the U.S. Department of Defense PC Research Program (HT94252310158). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. (© 2024 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu